CN102078284A - 一种含加替沙星的眼用凝胶剂及其制备方法 - Google Patents
一种含加替沙星的眼用凝胶剂及其制备方法 Download PDFInfo
- Publication number
- CN102078284A CN102078284A CN2009101783991A CN200910178399A CN102078284A CN 102078284 A CN102078284 A CN 102078284A CN 2009101783991 A CN2009101783991 A CN 2009101783991A CN 200910178399 A CN200910178399 A CN 200910178399A CN 102078284 A CN102078284 A CN 102078284A
- Authority
- CN
- China
- Prior art keywords
- gel
- eye
- gatifloxacin
- water
- carbomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 title claims abstract description 72
- 229960003923 gatifloxacin Drugs 0.000 title claims abstract description 72
- 238000002360 preparation method Methods 0.000 title claims abstract description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 64
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 48
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 48
- 229960001631 carbomer Drugs 0.000 claims abstract description 48
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 34
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 14
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 14
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 239000011159 matrix material Substances 0.000 claims abstract description 5
- 230000000844 anti-bacterial effect Effects 0.000 claims description 40
- 239000000243 solution Substances 0.000 claims description 26
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- 239000003889 eye drop Substances 0.000 claims description 21
- 230000003204 osmotic effect Effects 0.000 claims description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 18
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 18
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 18
- 230000008961 swelling Effects 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 229960003943 hypromellose Drugs 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 11
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 11
- 230000001954 sterilising effect Effects 0.000 claims description 11
- 238000004659 sterilization and disinfection Methods 0.000 claims description 11
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 229960005323 phenoxyethanol Drugs 0.000 claims description 10
- -1 polyoxyethylene Polymers 0.000 claims description 10
- 239000000758 substrate Substances 0.000 claims description 10
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 9
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 9
- 229960004926 chlorobutanol Drugs 0.000 claims description 9
- 229920000136 polysorbate Polymers 0.000 claims description 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 8
- 229910021538 borax Inorganic materials 0.000 claims description 8
- 239000004328 sodium tetraborate Substances 0.000 claims description 8
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 229960002233 benzalkonium bromide Drugs 0.000 claims description 6
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 5
- 239000004327 boric acid Substances 0.000 claims description 5
- 239000004359 castor oil Substances 0.000 claims description 4
- 235000019438 castor oil Nutrition 0.000 claims description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
- 239000012982 microporous membrane Substances 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical class CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- 235000004443 Ricinus communis Nutrition 0.000 claims description 2
- 239000008351 acetate buffer Substances 0.000 claims description 2
- 239000008366 buffered solution Substances 0.000 claims description 2
- 229960000800 cetrimonium bromide Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 2
- 229960002216 methylparaben Drugs 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 239000002085 irritant Substances 0.000 abstract description 4
- 231100000021 irritant Toxicity 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 2
- 229920002385 Sodium hyaluronate Polymers 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- 229940010747 sodium hyaluronate Drugs 0.000 abstract 1
- 239000008215 water for injection Substances 0.000 description 23
- 239000003814 drug Substances 0.000 description 16
- 206010023683 lagophthalmos Diseases 0.000 description 11
- 229940079593 drug Drugs 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000002421 anti-septic effect Effects 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 5
- 210000004087 cornea Anatomy 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 206010023332 keratitis Diseases 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 206010020565 Hyperaemia Diseases 0.000 description 3
- 210000001742 aqueous humor Anatomy 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000000795 conjunctiva Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010064996 Ulcerative keratitis Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 201000007717 corneal ulcer Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- XUBOMFCQGDBHNK-UHFFFAOYSA-N gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCNC(C)C1 XUBOMFCQGDBHNK-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 231100000286 mucous membrane, eye irritation or corrosion testing Toxicity 0.000 description 2
- 239000003961 penetration enhancing agent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 206010015993 Eyelid oedema Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 201000007032 bacterial conjunctivitis Diseases 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000003079 ectropion Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000008025 hordeolum Diseases 0.000 description 1
- 238000007731 hot pressing Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 210000004083 nasolacrimal duct Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 229940061354 tequin Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940109235 zymar Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
结膜 |
A.充血(指睑结膜、球结膜部位)血管正常 0血管充血呈红色 1血管充血呈红色,血管不易分辨 2弥漫性充血呈紫红色 3 |
B.水肿无水肿 0轻微水肿(包括瞬膜) 1明显水肿,伴有部分睑外翻 2水肿至眼睑近半闭合 3水肿至眼睑超过半闭合 4 |
Claims (12)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101783991A CN102078284B (zh) | 2009-11-27 | 2009-11-27 | 一种含加替沙星的眼用凝胶剂及其制备方法 |
EP10832513.5A EP2526923B1 (en) | 2009-11-27 | 2010-11-23 | Ophthalmic gel of gatifloxacin and preparation method thereof |
PCT/CN2010/001880 WO2011063606A1 (zh) | 2009-11-27 | 2010-11-23 | 一种含加替沙星的眼用凝胶剂及其制备方法 |
US13/581,415 US8901131B2 (en) | 2009-11-27 | 2010-11-23 | Gatifloxacin-containing ophthalmic gel and preparation method thereof |
RU2012148042/15A RU2012148042A (ru) | 2009-11-27 | 2010-11-23 | Офтальмологический гель, содержащий гатифлоксацин, и способ его получения |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101783991A CN102078284B (zh) | 2009-11-27 | 2009-11-27 | 一种含加替沙星的眼用凝胶剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102078284A true CN102078284A (zh) | 2011-06-01 |
CN102078284B CN102078284B (zh) | 2013-06-12 |
Family
ID=44065832
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009101783991A Active CN102078284B (zh) | 2009-11-27 | 2009-11-27 | 一种含加替沙星的眼用凝胶剂及其制备方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8901131B2 (zh) |
EP (1) | EP2526923B1 (zh) |
CN (1) | CN102078284B (zh) |
RU (1) | RU2012148042A (zh) |
WO (1) | WO2011063606A1 (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102885770A (zh) * | 2012-11-02 | 2013-01-23 | 江苏吉贝尔药业有限公司 | 一种新的加替沙星滴眼液及其制备方法 |
CN102961324A (zh) * | 2012-11-16 | 2013-03-13 | 沈阳药科大学 | 一种溶菌酶眼用凝胶剂及其制备方法 |
CN103142463A (zh) * | 2013-03-05 | 2013-06-12 | 宁夏康亚药业有限公司 | 眼用药物组合物,其制备方法及应用 |
CN105769754A (zh) * | 2016-04-25 | 2016-07-20 | 珠海亿胜生物制药有限公司 | 一种不含防腐剂的甲硝唑凝胶及其制备方法 |
CN111249225A (zh) * | 2020-03-23 | 2020-06-09 | 江苏永达药业有限公司 | 一种盐酸莫西沙星眼用凝胶的制备方法 |
CN115708805A (zh) * | 2022-11-21 | 2023-02-24 | 山东诺明康药物研究院有限公司 | 一种盐酸贝西沙星原位凝胶滴眼液及其制备方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3310363A4 (en) * | 2015-06-18 | 2019-02-13 | Common Pharma, Inc | ANTIMICROBIAL FORMULATIONS |
RU2633055C1 (ru) * | 2016-09-23 | 2017-10-11 | Илья Александрович Марков | Офтальмологическая композиция для лечения конъюнктивитов, блефаритов и краевой язвы роговицы при местном применении |
RU2633054C1 (ru) * | 2016-09-23 | 2017-10-11 | Илья Александрович Марков | Фармацевтическая композиция в виде геля для лечения блефаритов |
CN107982219B (zh) * | 2017-11-30 | 2020-09-15 | 天津中医药大学 | 阳离子修饰的盐酸毛果芸香碱柔性纳米脂质体眼用制剂及制备方法 |
RU2669768C1 (ru) * | 2017-12-26 | 2018-10-16 | Илья Александрович Марков | Гелеобразные капли для лечения воспалительных заболеваний глаз, включая инфекционные, устойчивые к антибиотикам |
US20220265695A1 (en) | 2019-07-26 | 2022-08-25 | Proqr Therapeutics Ii B.V. | Opthalmic compositions comprising viscosifying polymers and nucleic acids |
CN113244380B (zh) * | 2021-06-29 | 2021-10-08 | 中美福源生物技术(北京)股份有限公司 | 一种温度敏感型凝胶损伤修复制剂及其应用 |
CN114796101A (zh) * | 2022-03-28 | 2022-07-29 | 江苏莹华生物制药有限公司 | 一种缓释凝胶剂及其制备方法和应用 |
CN116036154A (zh) * | 2023-01-13 | 2023-05-02 | 青岛大学 | 补水除螨抑菌水凝胶眼贴及其制备方法和应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1314452C (zh) * | 2002-04-22 | 2007-05-09 | 沈阳药科大学 | 具有适宜相转变温度的眼用原位凝胶制剂 |
CN1194664C (zh) * | 2002-08-19 | 2005-03-30 | 上海兴康医药研究开发有限公司 | 可滴眼用在体凝胶制剂及其制备方法 |
CN1448137A (zh) | 2003-04-30 | 2003-10-15 | 江苏扬子江药业集团有限公司 | 加替沙星外用及眼用凝胶制剂 |
CN1215844C (zh) * | 2004-04-18 | 2005-08-24 | 李东 | 加替沙星眼凝胶及其制备方法 |
CN100427091C (zh) | 2004-04-20 | 2008-10-22 | 沈阳药科大学 | 以hpmc为基质的加替沙星眼用凝胶剂及其制备方法 |
EP2078527A4 (en) * | 2006-10-12 | 2011-12-21 | Kyorin Seiyaku Kk | GATIFLOXACIN-CONTAINING AQUEOUS LIQUID PREPARATION |
CN101130083B (zh) * | 2007-08-07 | 2010-05-19 | 山东博士伦福瑞达制药有限公司 | 一种眼用组合物及其制作方法和用途 |
-
2009
- 2009-11-27 CN CN2009101783991A patent/CN102078284B/zh active Active
-
2010
- 2010-11-23 US US13/581,415 patent/US8901131B2/en active Active
- 2010-11-23 EP EP10832513.5A patent/EP2526923B1/en active Active
- 2010-11-23 WO PCT/CN2010/001880 patent/WO2011063606A1/zh active Application Filing
- 2010-11-23 RU RU2012148042/15A patent/RU2012148042A/ru unknown
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102885770A (zh) * | 2012-11-02 | 2013-01-23 | 江苏吉贝尔药业有限公司 | 一种新的加替沙星滴眼液及其制备方法 |
CN102961324A (zh) * | 2012-11-16 | 2013-03-13 | 沈阳药科大学 | 一种溶菌酶眼用凝胶剂及其制备方法 |
CN102961324B (zh) * | 2012-11-16 | 2014-06-25 | 沈阳药科大学 | 一种溶菌酶眼用凝胶剂及其制备方法 |
CN103142463A (zh) * | 2013-03-05 | 2013-06-12 | 宁夏康亚药业有限公司 | 眼用药物组合物,其制备方法及应用 |
CN103142463B (zh) * | 2013-03-05 | 2015-09-09 | 宁夏康亚药业有限公司 | 眼用药物组合物,其制备方法及应用 |
CN105769754A (zh) * | 2016-04-25 | 2016-07-20 | 珠海亿胜生物制药有限公司 | 一种不含防腐剂的甲硝唑凝胶及其制备方法 |
CN111249225A (zh) * | 2020-03-23 | 2020-06-09 | 江苏永达药业有限公司 | 一种盐酸莫西沙星眼用凝胶的制备方法 |
CN115708805A (zh) * | 2022-11-21 | 2023-02-24 | 山东诺明康药物研究院有限公司 | 一种盐酸贝西沙星原位凝胶滴眼液及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
US8901131B2 (en) | 2014-12-02 |
EP2526923A1 (en) | 2012-11-28 |
EP2526923A4 (en) | 2014-03-12 |
RU2012148042A (ru) | 2014-05-20 |
WO2011063606A1 (zh) | 2011-06-03 |
CN102078284B (zh) | 2013-06-12 |
US20130040960A1 (en) | 2013-02-14 |
EP2526923B1 (en) | 2016-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102078284B (zh) | 一种含加替沙星的眼用凝胶剂及其制备方法 | |
RU2108112C1 (ru) | Водная лекарственная композиция, обладающая свойством обратимого терморегулируемого гелеобразования | |
CN107847604B (zh) | 眼用原位凝胶处方 | |
Qi et al. | In vitro evaluation of enhancing effect of borneol on transcorneal permeation of compounds with different hydrophilicities and molecular sizes | |
CN101716214B (zh) | 含有蒲公英提取物的药物组合物及其制药用途和制备方法 | |
EP1938799B1 (en) | Compositions for treating and preventing posterior segment ophthalmic disorders and use thereof | |
CN101947309B (zh) | 人碱性成纤维细胞生长因子滴眼液及其制备方法 | |
KR20010012521A (ko) | 방부 조성물 | |
CN102085203B (zh) | 左氧氟沙星和醋酸泼尼松龙的眼用制剂及其制备方法 | |
Jothi et al. | In-situ ophthalmic gels for the treatment of eye diseases | |
JPH05201854A (ja) | 長期放出性眼用製剤 | |
CN110090294A (zh) | 具有改善的干燥保护和保留的眼用组合物 | |
JP6820658B2 (ja) | ジピリダモールを用いる眼疾患の治療において使用するための組成物 | |
MXPA03009349A (es) | Composicion farmaceutica a base de macrolidos para la aplicacion local en oftalmologia. | |
CN1302812C (zh) | 含海藻糖和玻璃酸的眼部用药传递系统及其制备方法 | |
US9901580B2 (en) | Methods of eye treatment using therapeutic compositions containing dipyridamole | |
CN105142670A (zh) | 用于治疗眼部炎性疾病的滴眼剂组合物及其制备方法 | |
CN103977011A (zh) | 含有曲伏前列素和噻吗洛尔的眼用凝胶剂及其制备方法 | |
WO2012068998A2 (zh) | 一种曲安奈德眼用制剂及其制备方法 | |
JP7358526B2 (ja) | 向上した眼の快適性を提供する組成物 | |
BR112021001339A2 (pt) | composições e métodos para tratar os olhos | |
JPH03109326A (ja) | フレロキサシン点眼液 | |
CN101579357A (zh) | 一种熊胆眼用即型凝胶 | |
CN100408046C (zh) | 大环内酯类抗生素玻璃酸钠眼用传输系统 | |
CN115212200B (zh) | 用于治疗糖尿病并发症的含葛根素的复方制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 110027 No. 12, 4, three street, Shenyang economic and Technological Development Zone, Liaoning, China Applicant after: SHENYANG XINGQI PHARMACEUTICAL Co.,Ltd. Address before: 110027 No. 12, 4, three street, Shenyang economic and Technological Development Zone, Liaoning, China Applicant before: SHENYANG SINQI PHARMACEUTICAL Co.,Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: SHENYANG XINGQI MEDICINE CO., LTD. TO: SHENYANG SINQI EYE PHARMACEUTICAL CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: No. 25 Xinyunhe Road, Shenyang Area, China (Liaoning) Pilot Free Trade Zone, Shenyang City, Liaoning Province, 110167 Patentee after: SHENYANG XINGQI PHARMACEUTICAL Co.,Ltd. Address before: 110027 No. 12, 4, three street, Shenyang economic and Technological Development Zone, Liaoning, China Patentee before: SHENYANG XINGQI PHARMACEUTICAL Co.,Ltd. |